Profile data is unavailable for this security.
About the company
Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.
- Revenue in INR (TTM)10.38bn
- Net income in INR3.13bn
- Incorporated1984
- Employees1.38k
- LocationConcord Biotech Ltd10th FloorNr. Prahladnagar Garden, 100ft RoadAHMEDABAD 380015IndiaIND
- Phone+91 7 968138700
- Fax+91 2 714222504
- Websitehttp://www.concordbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 155.81bn | 2.01k | 34.93 | -- | 31.03 | 6.79 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.08bn | 1.65k | 48.53 | -- | 40.93 | 9.97 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 164.60bn | 2.17k | 38.30 | 24.04 | 35.17 | 6.91 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 167.89bn | 940.00 | 175.14 | -- | 151.37 | 12.10 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 189.82bn | 995.00 | 34.38 | -- | 20.38 | 2.77 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 190.11bn | 3.08k | 50.05 | -- | 31.14 | 8.40 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 228.23bn | 1.38k | 72.89 | -- | 62.20 | 21.99 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 233.77bn | 14.86k | 37.12 | -- | 25.82 | 3.71 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 261.71bn | 6.01k | 176.97 | -- | 47.35 | 5.18 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Pfizer Ltd | 22.25bn | 6.09bn | 266.72bn | 1.72k | 43.83 | -- | 39.82 | 11.99 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 276.38bn | 4.02k | 16.89 | -- | 15.15 | 6.55 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
| J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 288.42bn | 5.31k | 50.21 | -- | 39.25 | 8.03 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 288.68bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 291.41bn | 1.05k | 121.06 | -- | 98.48 | 31.18 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 302.68bn | 6.72k | 1,088.60 | -- | 38.84 | 3.61 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Gland Pharma Ltd | 58.58bn | 7.22bn | 303.39bn | 4.22k | 42.01 | -- | 27.75 | 5.18 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Data as of Sep 19 2024. Currency figures normalised to Concord Biotech Ltd's reporting currency: Indian Rupee INR
10.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Mar 2024 | 2.26m | 2.16% |
| Max Life Insurance Co. Ltd.as of 31 Mar 2024 | 1.59m | 1.52% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Jul 2024 | 1.23m | 1.18% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Aug 2024 | 1.20m | 1.15% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Aug 2024 | 999.46k | 0.96% |
| Tata AIA Life Insurance Co. Ltd.as of 30 Aug 2024 | 993.34k | 0.95% |
| Edelweiss Asset Management Ltd.as of 31 Aug 2024 | 878.82k | 0.84% |
| Baroda BNP Paribas Asset Management India Pvt Ltd.as of 31 Aug 2024 | 694.32k | 0.66% |
| DSP Asset Managers Pvt. Ltd.as of 31 Aug 2024 | 624.57k | 0.60% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024 | 364.38k | 0.35% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
